

# بسم الله الرحمن الرحيم





# شبكة المعلومات الجامعية

## التوثيق الالكتروني والميكروفيلم



# جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

## قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها  
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



## يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار





# بعض الوثائق الأصلية تالفة







# بالرسالة صفحات لم ترد بالأصل



**New dietary factors implicated in the  
pathophysiology of microvascular  
complications in type 1 diabetes mellitus.**


Thesis

Submitted for partial fulfillment of  
the MD Degree in Pediatrics.

By

**Yasser El-Said Ali Behairy**

M.B., B.Ch- M.Sc in Pediatrics



69004

618.92462  
y. El

Under Supervision of

**Prof. Dr. Mona Hussein El-Samahi**


Professor of Pediatrics

Faculty of Medicine - Ain Shams University

**Prof. Dr. Safinaz Adel EL-Habashy**

Professor of Pediatrics

Faculty of Medicine - Ain Shams University



**Prof. Dr. Zeinab Mohamed Ramadan Talib**

Professor of Nutritional Biochemistry

Nutrition Institute, Cairo.

**Ass. Prof. Dr. Sahar Mohamed Ahmed Hassanein**

Ass. Professor of Pediatrics,

Faculty of Medicine- Ain Shams University

**Faculty of Medicine**

**Ain Shams University**

**2002**



# ACKNOWLEDGEMENT

First and foremost, thanks are all to Allah

I would like to express my great thanks, gratitude and respect to our eminent professor **Dr. Mona Hussein El-Samahi** Professor of pediatrics, Faculty of Medicine, Ain Shams University, For giving me the privilege of working under her kind supervision. Her generous help, fruitful advice and constant support were very important in achieving this work.

I greatly feel indebted to **Dr. Safinaz Adel EL-Habashy**, Professor of pediatrics, Faculty of Medicine, Ain Shams University, for her enthusiastic guidance and constant support. Her sincere effort and help will never be forgotten.

I am greatly grateful to **Dr. Zinab Mohamed Ramadan Talib**, Professor of Nutrition Biochemistry, Nutrition Institute, Cairo for her help and effort in achieving the practical part of the work.

I would like to express my deep gratitude to **Dr. Sahar Mohamed Ahmed Hassanein**, Assistant Professor of pediatrics, Faculty of Medicine, Ain Shams University, For his great encouragement and guidance for doing this work.

Many thanks and deep appreciation goes to **Dr. Omayma Mohamed Said**, Researcher in National Research Center, Dokki, Cairo, for assessment and guiding the dietetic part of this work.

Last but not least, I would like to convey my great thanks and gratitude to our dear diabetic patients, who participated in the work and to their families for their great help in achieving this work.





# TABLE OF CONTENTS

|                               |      |
|-------------------------------|------|
| <b>List of Abbreviations</b>  | i    |
| <b>List of Tables</b>         | iv   |
| <b>List of Figures</b>        | vi   |
| <b>Introduction</b>           | viii |
| <b>Aim of the Work</b>        | xi   |
| <b>Review of Literature</b>   | 1    |
| <b>Patient and Method</b>     | 77   |
| <b>Results</b>                | 85   |
| <b>Discussion</b>             | 116  |
| <b>Summary and Conclusion</b> | 136  |
| <b>Recommendations</b>        | 139  |
| <b>References</b>             | 140  |
| <b>Arabic Summary</b>         |      |

# LIST OF ABBREVIATIONS

|               |                                                  |
|---------------|--------------------------------------------------|
| <b>ACE</b>    | Angiotensin-converting enzyme                    |
| <b>ADA</b>    | American Diabetes Association                    |
| <b>AGE</b>    | Advanced glycation end products                  |
| <b>ALA</b>    | Alpha-linolenic acid                             |
| <b>BCO</b>    | Black current seed oil                           |
| <b>BMI</b>    | Body mass index                                  |
| <b>CAN</b>    | Cardiovascular autonomic neuropathy              |
| <b>CVD</b>    | Cardio vascular disease                          |
| <b>DBP</b>    | Diastolic blood pressure                         |
| <b>DCCT</b>   | Diabetes control and Complications Trial         |
| <b>DHA</b>    | Docosahexaenoic acid                             |
| <b>DKA</b>    | Diabetic ketoacidosis                            |
| <b>DM</b>     | Dibetes millitus.                                |
| <b>DN</b>     | Diabetic nephropathy                             |
| <b>DNA</b>    | Deoxyribonucleic acid                            |
| <b>EDRF</b>   | Endothelium-derived relaxing factor              |
| <b>EPA</b>    | Eicosapentaenoic acid                            |
| <b>EPO</b>    | Evening primrose oil.                            |
| <b>ESRD</b>   | End stage renal disease                          |
| <b>FA</b>     | Fatty acid                                       |
| <b>FN</b>     | False negative                                   |
| <b>FP</b>     | False positive                                   |
| <b>GAD</b>    | Glutamic acid decarboxylase                      |
| <b>GLC</b>    | Gas liquid chromatography                        |
| <b>GM-CSF</b> | Granulocyte-macrophage colony-stimulating factor |
| <b>Hb</b>     | Hemoglobin                                       |
| <b>HbA1c</b>  | Glycated hemoglobin                              |

|              |                                         |
|--------------|-----------------------------------------|
| <b>Hcy</b>   | Homocysteine                            |
| <b>HDL</b>   | High-density lipoprotein                |
| <b>HNF</b>   | Hepatic nuclear transcription factor    |
| <b>HPLC</b>  | High-performance liquid chromatographic |
| <b>Ht</b>    | Height                                  |
| <b>HT</b>    | hydroxy tryptophane                     |
| <b>IAA</b>   | Insulin auto antibodies                 |
| <b>ICAS</b>  | Include islet cell antibodies           |
| <b>ICF</b>   | Intra-cellular fluid                    |
| <b>IFG</b>   | Impaired fasting glycemia               |
| <b>IGT</b>   | Impaired glucose tolerance.             |
| <b>IHD</b>   | Ischemic heart disease                  |
| <b>L(a)</b>  | Lipoprotein (a)                         |
| <b>LA</b>    | Linoleic acid                           |
| <b>LDL</b>   | Low-density lipoprotein                 |
| <b>LPS</b>   | Lipopolysaccharide                      |
| <b>MA</b>    | Microalbuminuria                        |
| <b>MBS</b>   | Mean bloodsugar                         |
| <b>MODY</b>  | Maturity- onset diabetes in the young.  |
| <b>MTHFR</b> | Methylenetetrahydrofolate reductase     |
| <b>MUFA</b>  | Mono-unsaturated fatty acids            |
| <b>MVC</b>   | Micro-vascular complications            |
| <b>NPDR</b>  | Non-Proliferative diabetic retinopathy  |
| <b>NS</b>    | Non-significant.                        |
| <b>OGTT</b>  | Oral glucose tolerance test             |
| <b>PAD</b>   | Peripheral arterial disease             |
| <b>PAF</b>   | Platelet activating factor              |
| <b>PC</b>    | Percentile                              |
| <b>PCR</b>   | Polymerase chain reaction               |
| <b>PDR</b>   | Proliferative diabetic retinopathy      |
| <b>PG</b>    | Plasma glucose                          |
| <b>PN</b>    | Peripheral neuropathy                   |
| <b>PUFA</b>  | Polyunsaturated fatty acid)             |

|             |                                    |
|-------------|------------------------------------|
| <b>SBP</b>  | Systolic blood pressure            |
| <b>SD</b>   | Standard deviation                 |
| <b>SFAs</b> | Saturated fatty acids              |
| <b>Sig.</b> | Significant                        |
| <b>SMBG</b> | Daily Self monitored blood glucose |
| <b>SN</b>   | Serial number                      |
| <b>TG</b>   | Triglycerides                      |
| <b>TN</b>   | True negative                      |
| <b>TP</b>   | True positive                      |
| <b>UAE</b>  | Urinary albumin excretion          |
| <b>VEGF</b> | Vascular endothelial growth factor |
| <b>VWF</b>  | von- Willebrand factor             |
| <b>Wt</b>   | Weight                             |
| <b>ω</b>    | Omega                              |

# LIST OF TABLES

| <b>Table</b> | <b>Comment</b>                                                                                                                                 | <b>Page</b> |
|--------------|------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| Table 1      | Etiologic classification of diabetes mellitus                                                                                                  | 3           |
| Table 2      | Other specific types of diabetes                                                                                                               | 4           |
| Table 3      | Clinical classification of diabetic neuropathies                                                                                               | 25          |
| Table 4      | Stages of diabetic nephropathy                                                                                                                 | 32          |
| Table 5      | Infections associated with diabetes                                                                                                            | 36          |
| Table 6      | ADA Goals for Glycemic Control                                                                                                                 | 37          |
| Table 7      | Approximate Pharmacokinetic Parameters of Currently Available Insulin Preparations Following Subcutaneous Injection of an Average Patient Dose | 45          |
| Table 8      | Factors affecting the bioavailability and absorption rate of subcutaneously injected insulin                                                   | 46          |
| Table 9      | Showing biochemical indices of glycemic Control                                                                                                | 51          |
| Table 10     | Examples of fatty acids                                                                                                                        | 53          |
| Table 11     | Functional effects of $\omega$ 3 fatty acids in the cardio vascular system                                                                     | 59          |
| Table 12     | Effects of $\omega$ 3 fatty acids on factors involved in the pathophysiology of atherosclerosis and inflammation                               | 59          |
| Table 13     | Causes of Hyperhomocysteinemia                                                                                                                 | 69          |
| Table 14     | Comparison between all diabetic patients and control subjects, as regards clinical and laboratory parameters.                                  | 85          |
| Table 15     | Comparison between diabetic patients without MVC (Group A) and control subjects, as regards clinical and laboratory parameters.                | 87          |



|          |                                                                                                                                                     |     |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| Table 16 | Comparison between diabetic patients with MVC (Group B) and control subjects (Group C), as regards clinical and laboratory parameters.              | 89  |
| Table 17 | Comparison between diabetic patients with MVC (group B) and diabetic patients without MVC (group A), as regards clinical and laboratory parameters. | 91  |
| Table 18 | Correlation between plasma homocysteine and various clinical and laboratory parameters in all diabetics, group A, and group B.                      | 95  |
| Table 19 | Correlation between omega 3 fatty acid and various clinical and laboratory parameters in all diabetic patients, group A, and group B.               | 105 |
| Table 19 | Plasma homocysteine in diabetic with and without MVC was distributed.                                                                               | 108 |
| Table 20 | Plasma Linolenic acid ( $\omega 3$ ) (%) in diabetic with and without MVC was distributed.                                                          | 109 |
| Table 21 | Row clinical data of Group (A) diabetic patients                                                                                                    | 110 |
| Table 22 | Row Laboratory data of Group (A) diabetic patients.                                                                                                 | 111 |
| Table 23 | Row clinical data of controls.                                                                                                                      | 112 |
| Table 24 | Row Laboratory data of Controls.                                                                                                                    | 113 |
| Table 25 | Row clinical data of Group(B) diabetic patients.                                                                                                    | 114 |
| Table 26 | Row Laboratory data of Group(B) diabetic patients.                                                                                                  | 115 |